论文部分内容阅读
1973年德人Johannes Koch和GünterEngelhardt二氏报导合成β_2受体兴奋剂克喘素(Clenbuterol,NAB365)的衍生物,双氯氨苯恶唑烷。[5-(4-Amino-3·5-dichlor-phe-nyl)-3-tert-butyl-oxazolidine],江苏金坛县制药厂在1978年试制成功其盐酸盐,定名为喘敌素。药理实验用豚鼠作双氯氨苯恶唑烷的平喘实验,国外报导静脉注射的半数效应剂量(ED_(50))为6.4微克/公斤,比舒喘灵(Salbutamol 7.5微克/公斤)、克喘素(8.0微克/公斤)略小,与异丙喘宁(Qrciptenaline 76微克/公斤)相比仅及1/12。
In 1973, Johannes Koch and Günter Engelhardt from Germany reported that the derivative of Clenbuterol (NAB365), a derivative of β 2 receptor agonist, is bischlorobenzamide. [5- (4-Amino-3 · 5-dichlor-phe-nyl) -3-tert-butyl-oxazolidine], Jiangsu Jintan Pharmaceutical Factory in 1978, the successful trial of its hydrochloride, known as Cholesterol. Pharmacological experiments Guinea pigs were used for anti-asthmatic trials of bis-chlorobenzidine, ox-oxazolidin was reported to have a median effective dose (ED_ (50)) of 6.4 μg / kg for intravenous injection in the foreign country and 7.5 μg / kg for salbutamol Asthmatic (8.0 μg / kg) is slightly smaller and only 1/12 compared to Qrcipalinealine (76 μg / kg).